Hostname: page-component-7c8c6479df-ph5wq Total loading time: 0 Render date: 2024-03-28T18:50:49.063Z Has data issue: false hasContentIssue false

Amphetamine prescribing

Published online by Cambridge University Press:  02 January 2018

Andrew McBride
Affiliation:
House 56, Cardiff Royal Infirmary, Newport Road, Cardiff CF24 0SZ
Richard Pates
Affiliation:
House 56, Cardiff Royal Infirmary, Newport Road, Cardiff CF24 0SZ
John Merrill
Affiliation:
House 56, Cardiff Royal Infirmary, Newport Road, Cardiff CF24 0SZ
Lesley Peters
Affiliation:
Mental Health Services of Salford, Bury New Road, Prestwich, Manchester M25 3BL
Rights & Permissions [Opens in a new window]

Abstract

Type
The Columns
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 2002. The Royal College of Psychiatrists

Sir: We were interested to read of the survey by Moselhy et al about amphetamine prescribing (Psychiatric Bulletin, February 2002, 26, 61-62). In England and Wales, dexamphetamine is the second most commonly prescribed controlled drug, accounting for 4.4% of such prescriptions, with an estimated 900-1000 people receiving the drug as a harm reduction measure (Reference Strang and SheridanStrang & Sheridan, 1997).

There is more extensive evidence than that cited by Moselhy et al for the efficacy of dexamphetamine, but this is largely based on opportunistic clinical evaluation. Recognising this deficiency, the Department of Health has funded a pilot (n=60) randomised controlled trial of dexamphetamine and best available treatment in Manchester and South Wales. The strict inclusion and exclusion criteria are both pragmatic and clinically relevant. We have used a modified version of the Opiate Treatment Index (Reference Barrowcliff, Champney-Smith and McBrideBarrowcliff et al, 1999) to evaluate progress, supported by urine testing for continued use of street amphetamine. We would be interested to know if the services surveyed routinely tested their patients using this technique, which has been available for some time (Reference Tetlow and MerrillTetlow & Merrill, 1996). We have prescribed tablets only, as we have no evidence that these are crushed and injected.

In the absence of trial evidence we would agree that amphetamine prescribing should be restricted to specialist services. We intend that one of the outcomes of our study should be some clearer clinical guidelines for the treatment of dependent amphetamine users.

References

Barrowcliff, A., Champney-Smith, J. & McBride, A. J. (1999) Use of a modified version of the Opiate Treatment Index with amphetamine users: validation and pilot evaluation of a prescribing service. Journal of Substance Use, 4, 98103.Google Scholar
Strang, J. & Sheridan, J. (1997) Prescribing amphetamine to drug misusers: data from the 1995 national survey of community pharmacies. Addiction, 92, 833838.Google Scholar
Tetlow, V. A. & Merrill, J. (1996) Rapid determination of amphetamine stereo-isomer ratios in urine by gas chromatography–mass spectroscopy. Annals of Clinical Biochemistry, 33, 5054.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.